The response is physiological
Clegg LE, Penland RC, Bachina S et al (2019) Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions
That changed in 2023 when Cost Plus partnered with Coherus BioSciences to offer YUSIMRY (adalimumab-aqvh), a biosimilar of Humira, for $569.27 far below Humiras list price of approximately $7,000 per month [10]
While wealthy patients can afford consistent access, underserved populations remain at risk of being left behind
It should be noted that higher doses of semaglutide are more likely to cause significant weight loss than the lower doses that are administered via Rybelsus or Ozempic